$ITOX
IIOT-OXYS, Inc. Stock $itox

$itox Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168316822007692 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$49.40K	$23.00K	$5.280K
YoY Change	723.33%	335.66%
Cost Of Revenue	$4.850K	$5.140K	$1.280K
YoY Change	529.87%	301.56%
Gross Profit	$44.55K	$17.86K	$4.000K
YoY Change	751.82%	346.58%
Gross Profit Margin	90.18%	77.66%	75.76%
Selling, General & Admin	$140.1K	$158.8K	$208.5K
YoY Change	37.89%	-23.84%	-16.7%
% of Gross Profit	314.52%	889.1%	5213.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$12.48K	$12.47K	$12.48K
YoY Change	0.08%	-0.08%	0.0%
% of Gross Profit	28.01%	69.81%	312.0%
Operating Expenses	$152.6K	$171.3K	$221.0K
YoY Change	33.74%	-22.49%	-16.97%
Operating Profit	-$108.1K	-$153.4K	-$217.0K
YoY Change	-0.75%	-29.29%	-18.47%
Interest Expense	-$172.6K	$14.91K	-$118.8K
YoY Change	3.0%	-112.55%	150.11%
% of Operating Profit
Other Income/Expense, Net		$111.1K	$10.00K
YoY Change		1011.37%
Pretax Income	-$280.6K	-$42.30K	-$325.8K
YoY Change	17.07%	-87.02%	-1.23%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$301.7K	-$42.30K	-$325.8K
YoY Change	25.84%	-87.02%	-1.23%
Net Earnings / Revenue	-610.65%	-183.87%	-6170.64%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$1.554K
COMMON SHARES
Basic Shares Outstanding	321.6M shares	283.8M shares	209.7M shares
Diluted Shares Outstanding		287.3M shares	209.7M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.34K	$34.28K	$103.0K
YoY Change	-28.79%	-66.72%	112.39%
Cash & Equivalents	$33.34K	$34.28K	$103.0K
Short-Term Investments
Other Short-Term Assets	$7.770K	$7.770K	$7.770K
YoY Change	0.0%	0.0%	219.75%
Inventory
Prepaid Expenses	$7.773K	$7.773K
Receivables	$28.94K	$16.38K	$5.280K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$70.05K	$58.44K	$116.1K
YoY Change	6.34%	-49.65%	72.8%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$443.9K	$455.4K	$310.6K
YoY Change	48.91%	46.64%	-28.66%
TOTAL ASSETS
Total Short-Term Assets	$70.05K	$58.44K	$116.1K
Total Long-Term Assets	$443.9K	$455.4K	$310.6K
Total Assets	$513.9K	$513.8K	$426.6K
YoY Change	41.2%	20.44%	-15.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$133.4K	$159.6K	$180.1K
YoY Change	-17.23%	-11.38%	-10.73%
Accrued Expenses	$395.7K	$327.6K	$482.7K
YoY Change	60.11%	-32.14%	2.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$363.2K	$363.2K	$431.1K
YoY Change	55.75%	-15.76%
Total Short-Term Liabilities	$1.677M	$1.532M	$1.645M
YoY Change	42.75%	-6.86%	-51.5%
LONG-TERM LIABILITIES
Long-Term Debt	$104.3K	$104.3K	$36.70K
YoY Change	-60.96%	184.2%	0.0%
Other Long-Term Liabilities	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$105.3K	$105.3K	$37.70K
YoY Change	-60.73%	179.31%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.677M	$1.532M	$1.645M
Total Long-Term Liabilities	$105.3K	$105.3K	$37.70K
Total Liabilities	$1.782M	$1.638M	$1.683M
YoY Change	23.52%	-2.69%	-50.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.307M	-$9.005M
YoY Change	8.93%
Common Stock	$352.2K	$309.1K
YoY Change	59.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.813M	-$1.534M	-$1.256M
YoY Change
Total Liabilities & Shareholders Equity	$513.9K	$513.8K	$426.6K
YoY Change	41.2%	20.44%	-15.1%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$301.7K	-$42.30K	-$325.8K
YoY Change	25.84%	-87.02%	-1.23%
Depreciation, Depletion And Amortization	$12.48K	$12.47K	$12.48K
YoY Change	0.08%	-0.08%	0.0%
Cash From Operating Activities	-$185.5K	-$124.7K	-$127.2K
YoY Change	74.64%	-1.93%	-967.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$149.9K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	184.5K	85.52K	149.9K
YoY Change	269.0%	-42.96%	-71500.0%
NET CHANGE
Cash From Operating Activities	-185.5K	-124.7K	-127.2K
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	184.5K	85.52K	149.9K
Net Change In Cash	-950.0	-39.22K	22.75K
YoY Change	-98.31%	-272.4%	57.33%
FREE CASH FLOW
Cash From Operating Activities	-$185.5K	-$124.7K	-$127.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Address Address Line1 EntityAddressAddressLine1	705 Cambridge Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02141
	dei	City Area Code CityAreaCode	(401)
	dei	Local Phone Number LocalPhoneNumber	307-3092
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001290658
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50773
	dei	Entity Registrant Name EntityRegistrantName	IIOT-OXYS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	56-2415252
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	321578761	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34284	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46821	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16380	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11280	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7773	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7773	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	58437	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	65874	usd
CY2022Q3	ITOX	Originall Issuance Discount On Note Receivable OriginallIssuanceDiscountOnNoteReceivable	5661	usd
CY2021Q4	ITOX	Originall Issuance Discount On Note Receivable OriginallIssuanceDiscountOnNoteReceivable	0	usd
CY2022Q3	ITOX	Note Receivable Net NoteReceivableNet	194339	usd
CY2021Q4	ITOX	Note Receivable Net NoteReceivableNet	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	261062	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	298085	usd
CY2022Q3	us-gaap	Assets Assets	513838	usd
CY2021Q4	us-gaap	Assets Assets	363959	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	159583	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	161171	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	327554	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	247155	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	46425	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	46425	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	57148	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	363167	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	233167	usd
CY2022Q3	ITOX	Salaries Payable To Related Parties SalariesPayableToRelatedParties	284452	usd
CY2021Q4	ITOX	Salaries Payable To Related Parties SalariesPayableToRelatedParties	273926	usd
CY2022Q3	ITOX	Shares Payable To Officers SharesPayableToOfficers	12221	usd
CY2021Q4	ITOX	Shares Payable To Officers SharesPayableToOfficers	0	usd
CY2022Q3	ITOX	Unearned Interests UnearnedInterests	10192	usd
CY2021Q4	ITOX	Unearned Interests UnearnedInterests	0	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	328839	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	212816	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1532433	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1174660	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	104300	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	267152	usd
CY2022Q3	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	1000	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	1000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1637733	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1442812	usd
CY2022Q3	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	410400	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	186000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	25896	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	25896	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	25845	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	25845	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	26	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	26	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	309083423	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	309083423	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	220254395	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	220254395	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	309083	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	220255	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7162069	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7059098	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9005473	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8544232	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1534295	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1264853	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	513838	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	363959	usd
CY2022Q3	us-gaap	Revenues Revenues	23003	usd
CY2021Q3	us-gaap	Revenues Revenues	5280	usd
	us-gaap	Revenues Revenues	39503	usd
	us-gaap	Revenues Revenues	5280	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	5140	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1275	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5650	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1275	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	17863	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	4005	usd
	us-gaap	Gross Profit GrossProfit	33853	usd
	us-gaap	Gross Profit GrossProfit	4005	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12477	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12477	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37023	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37295	usd
	ITOX	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	158818	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	208531	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	543449	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	737746	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	171295	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	221008	usd
	us-gaap	Operating Expenses OperatingExpenses	580472	usd
	us-gaap	Operating Expenses OperatingExpenses	775041	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	125568	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-18103	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	277424	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	172558	usd
CY2022Q3	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	5504	usd
CY2021Q3	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	-0	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	207447	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	-0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	120000	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	5986	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	0	usd
	us-gaap	Interest Income Other InterestIncomeOther	11647	usd
	us-gaap	Interest Income Other InterestIncomeOther	0	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	14913	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	100701	usd
	us-gaap	Interest Expense InterestExpense	278605	usd
	us-gaap	Interest Expense InterestExpense	333039	usd
CY2022Q3	us-gaap	Other Income OtherIncome	0	usd
CY2021Q3	us-gaap	Other Income OtherIncome	10000	usd
	us-gaap	Other Income OtherIncome	0	usd
	us-gaap	Other Income OtherIncome	10000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	111137	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-108804	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-196981	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30481	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42295	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-325807	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-743600	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-801517	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-42295	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-325807	usd
	us-gaap	Net Income Loss NetIncomeLoss	-743600	usd
	us-gaap	Net Income Loss NetIncomeLoss	-801517	usd
CY2022Q3	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	6909	usd
CY2021Q3	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	5626	usd
	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	31617	usd
	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	16694	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49204	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-331433	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-775217	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-818211	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	287269793	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	287269793	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	209650048	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	209650048	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	256358480	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	256358480	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188036903	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188036903	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1571617	usd
CY2022Q3	ITOX	Common Stock Issued For Financing Commitment CommonStockIssuedForFinancingCommitment	88292	usd
CY2022Q3	ITOX	Sales Commissions Paid For Capital Raise SalesCommissionsPaidForCapitalRaise	-1766	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49204	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1534295	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1264853	usd
	ITOX	Common Stock Issued For Financing Commitment CommonStockIssuedForFinancingCommitment	481657	usd
	ITOX	Sales Commissions Paid For Capital Raise SalesCommissionsPaidForCapitalRaise	-9633	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	900	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	90000	usd
	ITOX	Beneficial Conversion Feature Associated With Discounts BeneficialConversionFeatureAssociatedWithDiscounts	-57149	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-775217	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1534295	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1340942	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	80000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	153000	usd
CY2021Q3	ITOX	Commission Paids For Raising Capital CommissionPaidsForRaisingCapital	-3060	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-331433	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1442435	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2541280	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	323520	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	532500	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	360000	usd
	ITOX	Commission Paids For Raising Capital CommissionPaidsForRaisingCapital	-10650	usd
	ITOX	Common Stock Issued For Accrued Compensation CommonStockIssuedForAccruedCompensation	702986	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	8700	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-818211	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1442435	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-775217	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-818211	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	120000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	900	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	ITOX	Discount On Notes Receivable DiscountOnNotesReceivable	5661	usd
	ITOX	Discount On Notes Receivable DiscountOnNotesReceivable	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37400	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	269734	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37023	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37295	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-0	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5346	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5100	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5280	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1588	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10167	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	80398	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	84755	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	116023	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-172558	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	10192	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	12221	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	333950	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	10526	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-136417	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-471561	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-521911	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	200000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	481657	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	521850	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9633	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	187000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	659024	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	521850	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12537	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-61	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46821	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103074	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34284	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103013	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	ITOX	Conversion Of Convertible Notes Payable And Derivative Liabilities ConversionOfConvertibleNotesPayableAndDerivativeLiabilities	0	usd
	ITOX	Conversion Of Convertible Notes Payable And Derivative Liabilities ConversionOfConvertibleNotesPayableAndDerivativeLiabilities	1035206	usd
	ITOX	Beneficial Conversion Feature Discount On Notes Payable BeneficialConversionFeatureDiscountOnNotesPayable	0	usd
	ITOX	Beneficial Conversion Feature Discount On Notes Payable BeneficialConversionFeatureDiscountOnNotesPayable	360000	usd
	ITOX	Effect Of Adopting Asu202006 EffectOfAdoptingAsu202006	57149	usd
	ITOX	Effect Of Adopting Asu202006 EffectOfAdoptingAsu202006	0	usd
CY2022Q3	ITOX	Working Capital WorkingCapital	1473996	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-471561	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9005473	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zsSYI28d37L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z6U1ZHCqCbs7">Reclassifications</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37023	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zMLx9phRrSCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zrV6QEuYrz0k">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related parties. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34284	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46821	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16380	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11280	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37295	usd
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0	shares
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	543167	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_z1mwAZBRKtk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_865_zHyQS5VO1jma">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially expose the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company’s policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“<b>FDIC</b>”), up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_c20220930_pp0p0" title="FDIC insured amount">250,000</span>. At September 30, 2022 and December 31, 2021, the Company had <span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20220930_zUBHn7xFjUcb" title="Cash in excess of FDIC insurance"><span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20211231_zPx4BOq9uX95" title="Cash in excess of FDIC insurance">no</span></span> amounts in excess of the FDIC insurance limit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q3	ITOX	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
CY2021Q3	ITOX	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-775217	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-818211	usd
	ITOX	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	256358480	shares
	ITOX	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	188036903	shares
	ITOX	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	261062	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	298085	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	495000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	495000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	233938	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	196915	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	261062	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	298085	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12477	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12477	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12477	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	49500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	49500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	49500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	49500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	50585	usd
CY2022Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	261062	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	633167	usd
CY2022Q3	ITOX	Deferred Financing Costs DeferredFinancingCosts	75700	usd
CY2021Q4	ITOX	Deferred Financing Costs DeferredFinancingCosts	75700	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-0	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	57148	usd
CY2022Q3	ITOX	Convertible Notes Payable Net ConvertibleNotesPayableNet	467467	usd
CY2021Q4	ITOX	Convertible Notes Payable Net ConvertibleNotesPayableNet	500319	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	363167	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	233167	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	104300	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	267152	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49204	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-331433	usd
CY2022Q3	ITOX	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	287269793	shares
CY2021Q3	ITOX	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	209650048	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	368836113	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	326351314	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	309083423	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	309083423	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	25896	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	25896	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	14000000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.008081
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	14000000	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3600000	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	3600000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.30
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.0031
CY2022Q3	ITOX	Valuation Price ValuationPrice	0.0032
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.7744	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0405	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P1Y6M
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2868397	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.00084
	ITOX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms	P3Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2868397	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00084
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2868397	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.00084
	ITOX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms	P2Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2868397	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.00084
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y8M12D

Files In Submission

Name	View Source	Status
0001683168-22-007692-index-headers.html	Edgar Link	pending
0001683168-22-007692-index.html	Edgar Link	pending
0001683168-22-007692.txt	Edgar Link	pending
0001683168-22-007692-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
iiot_ex3101.htm	Edgar Link	pending
iiot_ex3102.htm	Edgar Link	pending
iiot_ex3201.htm	Edgar Link	pending
iiot_ex3202.htm	Edgar Link	pending
iiot_i10q-093022.htm	Edgar Link	pending
itox-20220930.xsd	Edgar Link	pending
itox-20220930_pre.xml	Edgar Link	unprocessable
itox-20220930_lab.xml	Edgar Link	unprocessable
itox-20220930_def.xml	Edgar Link	unprocessable
itox-20220930_cal.xml	Edgar Link	unprocessable
iiot_i10q-093022_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITOX
IIOT-OXYS, Inc. Stock $itox

2022 Q4 Form 10-Q Financial Statement

#000168316822007692 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOX IIOT-OXYS, Inc. Stock $itox

2022 Q4 Form 10-Q Financial Statement

#000168316822007692 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOX
IIOT-OXYS, Inc. Stock $itox